ストックスクリーナーアプリを入手
208.99
0.27%
0.57
アフターアワーズ：
209.17
0.18
+0.09%
前日終値:
$208.42
開ける：
$207.78
24時間の取引高:
5.06M
Relative Volume:
0.72
時価総額：
$369.65B
収益：
$61.16B
当期純損益:
$4.19B
株価収益率:
88.50
EPS:
2.3614
ネットキャッシュフロー:
$17.82B
1週間 パフォーマンス:
-1.61%
1か月 パフォーマンス:
-5.63%
6か月 パフォーマンス:
-7.88%
1年 パフォーマンス:
+21.73%
1日の値動き範囲:
$206.52
$209.66
1週間の範囲:
$203.01
$214.10
52週間の値動き範囲:
$168.54
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Compare ABBV vs LLY, JNJ, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
208.99 | 368.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
903.99 | 808.52B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.54 | 574.86B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
200.47 | 312.04B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
149.73 | 290.19B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-04 | ダウングレード | DZ Bank | Buy → Hold |
| 2025-10-14 | ダウングレード | Erste Group | Buy → Hold |
| 2025-10-01 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial - TipRanks
AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors - TipRanks
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
Nations Financial Group Inc. IA ADV Has $4.88 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Lbp Am Sa Purchases 8,678 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie eases the pain with $745m licensing deal - BioXconomy
Cwm LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
Adelphi Trust Co Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
Operating expenses (excl. COGS) of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally - Yahoo Finance
Spectrum Asset Management Reduces AbbVie Stake - National Today
NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan - Barchart.com
RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148 - AASTOCKS.com
AbbVie Inc. $ABBV Shares Purchased by Farther Finance Advisors LLC - MarketBeat
Bingham Private Wealth LLC Purchases Shares of 5,019 AbbVie Inc. $ABBV - MarketBeat
Franklin Income Focus ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc.: - marketscreener.com
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore
AbbVie Inc. stock (US00287Y1091): Is its immunology dominance strong enough to unlock new upside? - AD HOC NEWS
AbbVie (NYSE:ABBV) Shares Up 1.9%Should You Buy? - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
BRAF Mutated Non-small Cell Lung Cancer Market: Rapid Increment Driven by Innovation by 2036 – DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal - BioWorld News
Could AbbVie Crash Lilly's Weight‑Loss Party? - The Globe and Mail
AbbVie Inc. stock (US00287Y1091): Is immunology dominance strong enough to unlock new upside? - AD HOC NEWS
ABBV stock shows mixed momentum on neutral MACD reading: weekly review - Traders Union
Natural Investments Trims Stake in AbbVie - National Today
JM2 Capital Inc. Buys Shares of 2,519 AbbVie Inc. - National Today
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation - AbbVie News Center
Erin Lichy shares her breast augmentation story in Natrelle campaign - Stock Titan
Patton Fund Management Inc. Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Rede Wealth LLC - MarketBeat
Haisco Pharma strikes deal with AbbVie to develop novel pain medicines - The Pharma Letter
AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story - Yahoo Finance
What is behind AbbVie stock's recent drop in value today - Traders Union
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial - Yahoo
Haisco Grants AbbVie Exclusive Rights to Advance Novel Pain Medicines - Contract Pharma
Abbvie licenses ex-China rights to Haisco pain compounds - BioWorld News
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1? - Yahoo Finance
AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid - Pharmaceutical Technology
AbbVie (ABBV) Ends Development Agreement, CollPlant Eyes New Opp - GuruFocus
CollPlant announces termination of development agreement with AbbVie - TipRanks
CollPlant ends AbbVie deal, cuts workforce by 50% - Investing.com Canada
AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50% - Stock Titan
DB&C Advisors, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV) Partners with Haisco for Pain Therapy Development - GuruFocus
Haisco Pharmaceutical Group Co., Ltd. Enters Exclusive License Agreement with AbbVie - marketscreener.com
AbbVie, Inc. Trade Ideas — BSESOF:4AB - TradingView — Track All Markets
Haisco licenses pain drug candidates to AbbVie for $745 million By Investing.com - Investing.com Canada
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
0.34%
大文字化:
|
ボリューム (24 時間):